LDN-214117

CAS# 1627503-67-6

LDN-214117

Catalog No. BCC5528----Order now to get a substantial discount!

Product Name & Size Price Stock
LDN-214117: 5mg $81 In Stock
LDN-214117: 10mg Please Inquire In Stock
LDN-214117: 20mg Please Inquire Please Inquire
LDN-214117: 50mg Please Inquire Please Inquire
LDN-214117: 100mg Please Inquire Please Inquire
LDN-214117: 200mg Please Inquire Please Inquire
LDN-214117: 500mg Please Inquire Please Inquire
LDN-214117: 1000mg Please Inquire Please Inquire
Related Products
  • SB 431542

    Catalog No.:BCC3658
    CAS No.:301836-41-9
  • SB525334

    Catalog No.:BCC2531
    CAS No.:356559-20-1
  • A 77-01

    Catalog No.:BCC1318
    CAS No.:607737-87-1
  • SD-208

    Catalog No.:BCC1938
    CAS No.:627536-09-8
  • LY2109761

    Catalog No.:BCC3806
    CAS No.:700874-71-1
  • LY2157299

    Catalog No.:BCC3709
    CAS No.:700874-72-2

Quality Control of LDN-214117

Number of papers citing our products

Chemical structure

LDN-214117

3D structure

Chemical Properties of LDN-214117

Cas No. 1627503-67-6 SDF Download SDF
PubChem ID 91754554 Appearance Powder
Formula C25H29N3O3 M.Wt 419.52
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (238.37 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine
SMILES CC1=C(C=C(C=N1)C2=CC=C(C=C2)N3CCNCC3)C4=CC(=C(C(=C4)OC)OC)OC
Standard InChIKey BHUXVRVMMYAXKN-UHFFFAOYSA-N
Standard InChI InChI=1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of LDN-214117

DescriptionPotent and selective inhibitor of type I bone morphogenic protein (BMP) receptor ALK2 (IC50 = 24 nM). Shows preference for ALK1 and ALK2 over ALK3 and 164-fold selectivity for BMP6 inhibition (IC50 = 100 nM) over TGF-β1. Exhibits improved kinome selectivity over K 02288 (Cat.No. 4986) and low cytotoxicity.

LDN-214117 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

LDN-214117 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of LDN-214117

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.3837 mL 11.9184 mL 23.8368 mL 47.6735 mL 59.5919 mL
5 mM 0.4767 mL 2.3837 mL 4.7674 mL 9.5347 mL 11.9184 mL
10 mM 0.2384 mL 1.1918 mL 2.3837 mL 4.7674 mL 5.9592 mL
50 mM 0.0477 mL 0.2384 mL 0.4767 mL 0.9535 mL 1.1918 mL
100 mM 0.0238 mL 0.1192 mL 0.2384 mL 0.4767 mL 0.5959 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on LDN-214117

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.[Pubmed:25101911]

J Med Chem. 2014 Oct 9;57(19):7900-15.

There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors. Here we describe the structure-activity relationship for a series of novel ALK2 inhibitors based on the 2-aminopyridine compound K02288. Several modifications increased potency in kinase, thermal shift, or cell-based assays of BMP signaling and transcription, as well as selectivity for ALK2 versus closely related BMP and TGF-beta type I receptor kinases. Compounds in this series exhibited a wide range of in vitro cytotoxicity that was not correlated with potency or selectivity, suggesting mechanisms independent of BMP or TGF-beta inhibition. The study also highlights a potent 2-methylpyridine derivative 10 (LDN-214117) with a high degree of selectivity for ALK2 and low cytotoxicity that could provide a template for preclinical development. Contrary to the notion that activating mutations of ALK2 might alter inhibitor efficacy due to potential conformational changes in the ATP-binding site, the compounds demonstrated consistent binding to a panel of mutant and wild-type ALK2 proteins. Thus, BMP inhibitors identified via activity against wild-type ALK2 signaling are likely to be of clinical relevance for the diverse ALK2 mutant proteins associated with FOP and DIPG.

Description

LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM; > 100 fold selectivity for ALK5; also inhibits BMP6(IC50=100 nM).

Keywords:

LDN-214117,1627503-67-6,Natural Products,ALK, buy LDN-214117 , LDN-214117 supplier , purchase LDN-214117 , LDN-214117 cost , LDN-214117 manufacturer , order LDN-214117 , high purity LDN-214117

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: